Akèy › Kansè Poumon ki pa ti selil › New York › Shirley
Etid klinik pou Kansè Poumon ki pa ti selil nan Shirley, NY
5 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Shirley (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Ap rekriteFaz 1/2
- New York Cancer And Blood Specialists - Shirley /ID# 272547, Shirley
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- New York Cancer and Blood Specialists, Shirley
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- New York Cancer & Blood Specialists, Shirley
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Shirley
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Riverhead · 13 mi lwen
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- New York Cancer & Blood Specialists (NYCBS), Shirley
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Shirley
- Kansè kolorektal6 etid
- Maladi kadyovaskilè4 etid
- Kansè nan tete3 etid
- Kansè Metastatik3 etid
- Kansè (tout kalite)3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.